Curza is a small-molecule therapeutics company dedicated to addressing the critical issue of antibiotic resistance, which poses a significant threat to global health. The company has developed several proprietary drug classes aimed at combating infectious diseases, particularly focusing on drug-resistant Gram-negative bacteria. Their lead program, CZ-02, represents a new class of broad-spectrum antibiotics specifically targeting ESKAPE pathogens, which are notorious for their resistance to existing treatments. This innovative approach is inspired by natural products and aims to exploit an unexploited binding site on the bacterial ribosome, thereby enhancing the efficacy of antibiotic treatments.

In addition to their broad-spectrum antibiotics, Curza is also focused on developing antibiofilm antibiotics to tackle infections associated with biofilms, which can complicate conditions such as tuberculosis, diabetic ulcers, and chronic skin wounds. The company has designed two novel classes of antibiotics that demonstrate potent activity against various ESKAPE pathogens, showcasing their commitment to creating effective solutions in the fight against antibiotic-resistant infections. Through their research and development efforts, Curza aims to significantly reduce the impact of antibiotic resistance, which currently contributes to millions of deaths annually.

United States

Curza is a small molecule therapeutics development company.  Curza has developed a new class of antibiotics that are active and selective against Gram-negative pathogens.

Curza

Company Details